| The Caries Management Support System (CMS System) will be targeted at the US and European markets — where there are around 430,000 dentists — and the process of obtaining the necessary regulatory approval for the system in both markets is said to be well advanced.
Details behind the plans for a 2006 commercial launch of the system emerged today as the Dundee Technology Park –based company behind its development, IDMoS plc, announced its latest set of interim results.
The Alternative Investment Market (AIM) listed company also indicated that development of another sophisticated dental care product — a 3D CMS system — has been accelerated and could now be made available to the market within 12 to 18 months.
IDMoS also confirmed today that work involving turning its technology towards the battle against cancer is also gathering pace.
Principally through a tie-up with Polish research organisation ESKULAP, some innovative developments in the area of non-invasive tumour detection and monitoring are now being progressed.
“We have made some good progress in this area,” IDMoS chief executive Stephen Westwood told the Evening Telegraph. “There is not a great deal more we can say at this stage because of commercial sensitivities, but we hope to make an announcement in due course.”
Floated in November, 2004, IDMoS raised £4.6 million gross through the move and a further £2.3m of investment through another share placing less than a year later.
Additional investment has also come from a tie-up between IDMoS and US dental equipment distributor Dentsply and through grants.
Research and development and other costs have absorbed most of the investment to date and this has been reflected in the interim results for the six months to January 31, released by IDMoS today, with the company announcing consolidated pre-tax loss for the period of £1.12 million. The figure, which compares with a loss of £725,000 for the comparable period last year, was described by chairman John K Pool as reflecting “substantial product development costs in line with the board’s expectations”.
A new senior appointment to the company was also announced today.
Andrew Greaves has become the dental business commercial manager, joining IDMoS from Oxford University spin-out company Oxford Immunotec Limited, which specialises in the diagnosis of latent and active tuberculosis, where he was export manager. |
